315 related articles for article (PubMed ID: 9052751)
21. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
22. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
23. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
24. Distinct patterns of expression and physiological effects of sst1 and sst2 receptor subtypes in mouse hypothalamic neurons and astrocytes in culture.
Viollet C; Lanneau C; Faivre-Bauman A; Zhang J; Djordjijevic D; Loudes C; Gardette R; Kordon C; Epelbaum J
J Neurochem; 1997 Jun; 68(6):2273-80. PubMed ID: 9166719
[TBL] [Abstract][Full Text] [Related]
25. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
26. Pituitary somatostatin receptor (sst)1-5 expression during rat development: age-dependent expression of sst2.
Reed DK; Korytko AI; Hipkin RW; Wehrenberg WB; Schonbrunn A; Cuttler L
Endocrinology; 1999 Oct; 140(10):4739-44. PubMed ID: 10499533
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
28. Somatostatin receptors in pituitary function, diagnosis and therapy.
Hofland LJ; Lamberts SW
Front Horm Res; 2004; 32():235-52. PubMed ID: 15281350
[TBL] [Abstract][Full Text] [Related]
29. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
30. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer.
Buscail L; Saint-Laurent N; Chastre E; Vaillant JC; Gespach C; Capella G; Kalthoff H; Lluis F; Vaysse N; Susini C
Cancer Res; 1996 Apr; 56(8):1823-7. PubMed ID: 8620499
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor expression and patients' response to targeted medical treatment in pituitary tumors: evidences and controversies.
Gatto F; Arvigo M; Ferone D
J Endocrinol Invest; 2020 Nov; 43(11):1543-1553. PubMed ID: 32557353
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of multiple somatostatin receptors in the rat cerebellum during development.
Viollet C; Bodenant C; Prunotto C; Roosterman D; Schaefer J; Meyerhof W; Epelbaum J; Vaudry H; Leroux P
J Neurochem; 1997 Jun; 68(6):2263-72. PubMed ID: 9166718
[TBL] [Abstract][Full Text] [Related]
33. Chronic treatment with estrogen up-regulates expression of sst2 messenger ribonucleic acid (mRNA) but down-regulates expression of sst5 mRNA in rat pituitaries.
Kimura N; Tomizawa S; Arai KN; Kimura N
Endocrinology; 1998 Apr; 139(4):1573-80. PubMed ID: 9528936
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor subtypes sst1 and sst2 elicit opposite effects on the response to glutamate of mouse hypothalamic neurones: an electrophysiological and single cell RT-PCR study.
Lanneau C; Viollet C; Faivre-Bauman A; Loudes C; Kordon C; Epelbaum J; Gardette R
Eur J Neurosci; 1998 Jan; 10(1):204-12. PubMed ID: 9753128
[TBL] [Abstract][Full Text] [Related]
35. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy.
Ben-Shlomo A; Schmid H; Wawrowsky K; Pichurin O; Hubina E; Chesnokova V; Liu NA; Culler M; Melmed S
J Clin Endocrinol Metab; 2009 Nov; 94(11):4342-50. PubMed ID: 19820006
[TBL] [Abstract][Full Text] [Related]
36. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptors in the rhesus monkey brain: localization and pharmacological characterization.
Thoss VS; Piwko C; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1996 May; 353(6):648-60. PubMed ID: 8738298
[TBL] [Abstract][Full Text] [Related]
38. Expression of somatostatin receptor subtypes in human brain tumors.
Dutour A; Kumar U; Panetta R; Ouafik L; Fina F; Sasi R; Patel YC
Int J Cancer; 1998 May; 76(5):620-7. PubMed ID: 9610716
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin sst2 receptor knock-out mice: localisation of sst1-5 receptor mRNA and binding in mouse brain by semi-quantitative RT-PCR, in situ hybridisation histochemistry and receptor autoradiography.
Hannon JP; Petrucci C; Fehlmann D; Viollet C; Epelbaum J; Hoyer D
Neuropharmacology; 2002 Mar; 42(3):396-413. PubMed ID: 11897118
[TBL] [Abstract][Full Text] [Related]
40. sst1 mRNA is the prominent somatostatin receptor mRNA in the rat gastrointestinal tract: reverse transcription polymerase chain reaction and in situ-hybridization study.
Schäfer J; Meyerhof W
Neuropeptides; 1999 Dec; 33(6):457-63. PubMed ID: 10657524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
